Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#How Has The Imfinzi (durvalumab) Market Size Shifted, And What Is the Outlook Through 2034?
The market size of Imfinzi (durvalumab) has experienced accelerated growth recently. Projection suggests that its worth will escalate from $2,701.22 million in 2024 to $3,013.33 million in 2025, reflecting a compound annual growth rate (CAGR) of 11.6%. The growth that the historical period has witnessed can be linked to several factors such as broadened indications and approvals, the increasing preference for targeted therapies, a surge in patient interest in personalized treatments, advancements in immunotherapy, and a heightened demand for immunotherapies among patients.
How Much Will the Imfinzi (durvalumab) Market Be Worth in 2029?
Anticipated to experience a rapid increase in the coming years, the market size for imfinzi (durvalumab) is projected to reach $4,143.36 million by 2029, with a compound annual growth rate (CAGR) of 11.3%. This growth during the forecast period is credited to the escalating use of combined therapies, an uptick in pharmaceutical research and development, a surge in cancer rates, wider acceptance of immunotherapy, an expanding regulatory context, and increased investments in healthcare facilities. Significant trends during this forecast period encompass the embrace of personalized medicine methods, the drive towards individualized medicine, the uptake of biosimilars, the incorporation of artificial intelligence and machine learning, and partnerships among pharmaceutical companies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19906&type=smp
Which is the Largest Company in the Imfinzi (durvalumab) Market?
Major companies operating in the imfinzi (durvalumab) market include AstraZeneca PLC.
What Are the Main Market Drivers in the Imfinzi (durvalumab) Industry?
The increasing prevalence of cancer is anticipated to fuel the expansion of the Imfinzi (durvalumab) market in the future. Cancer is an umbrella term for a cluster of diseases marked by the unregulated multiplication and dissemination of anomalous cells in the body, which may infiltrate and demolish conventional tissues. This escalation in cancer cases is primarily due to an ageing demographic, as cancer risk heightens with age, along with lifestyle elements such as smoking, unhealthy eating habits, and obesity that escalate cancer rates. Durvalumab (Imfinzi) treats cancer by obstructing the PD-L1 protein, preventing the cancer cells from avoiding detection by the immune system. For example, the National Cancer Institute (NIH), a US-based governmental institution, reported in May 2024, that in 2022, there were 18.1 million cancer survivors in the U.S, estimated to surge to 22.5 million by 2032. Therefore, the increasing prevalence of cancer is fuelling the growth of the Imfinzi (durvalumab) market. The Surge In Personalized Medicine Boosts The Growth Of The Imfinzi (durvalumab) Market
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=19906&type=smp
How Is the Imfinzi (durvalumab) Market Segments Structured?
The imfinzi (durvalumab)market covered in this report is segmented –
1) By Type: 2.4mL Injection; 10mL Injection
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By Application: Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Other Applications
What Strategic Trends Are Transforming the Imfinzi (durvalumab) Market?
The primary trend in the Imfinzi (durvalumab) industry is focusing on acquiring regulatory approvals to broaden its application to more cancer forms, boost its clinical indications, and extend its market accessibility. Regulatory approvals are official permissions bestowed by health regulatory bodies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), enabling the marketing and application of a drug, medical device, or treatment in particular regions. For example, in September 2022, AstraZeneca, a pharmaceutical corporation based in the UK, achieved FDA approval for durvalumab (Imfinzi) to serve as a treatment for locally advanced or metastatic biliary tract cancer (BTC) in adults, founded on the findings of the TOPAZ-1 trial. This vital study revealed that when durvalumab was joined with gemcitabine and cisplatin, it notably boosted overall survival (12.8 months vs. 11.5 months for placebo) and progression-free survival (7.2 months vs. 5.7 months). The research involved 685 patients with varied forms of BTC, with common side effects including fatigue, nausea, and abdominal pain. The proposed dosage is 1,500 mg every three weeks during combined therapy, followed by monotherapy each four weeks.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/imfinzi-durvalumab-global-market-report
Which Global Regions Offer the Highest Growth in the Imfinzi (durvalumab) Market?
North America was the largest region in the imfinzi (durvalumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the imfinzi (durvalumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19906
This Report Delivers Insight On:
1. How big is the imfinzi (durvalumab) market, and how is it changing globally?
2. Who are the major companies in the imfinzi (durvalumab) market, and how are they performing?
3. What are the key opportunities and risks in the imfinzi (durvalumab) market right now?
4. Which products or customer segments are growing the most in the imfinzi (durvalumab) market?
5. What factors are helping or slowing down the growth of the imfinzi (durvalumab) market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model